institutional review boards (IRBs) are integral to the U.S. system of protection of human research participants. Evaluation of IRBs, although difficult, is essential. To date, no systematic review of IRB studies has been published. We conducted a systematic review of empirical studies of U.S. IRBs to determine what is known about the function of IRBs and to identify gaps in knowledge. A structured search in PubMed identified forty-three empirical studies evaluating U.S. IRBs. Studies were included if they reported an empirical investigation of the structure, process, outcomes, effectiveness, or variation of U.S. IRBs. The authors reviewed each study to extract information about study objectives, sample and methods, study results, and conclusions. Empirical evidence collected in forty-three published studies shows that for review of a wide range of types of research, U.S. IRBs differ in their application of the federal regulations, in the time they take to review studies, and in the decisions made. Existing studies show evidence of variation in multicenter review, inconsistent or ambiguous interpretation of the federal regulations, and inefficiencies in review. Despite recognition of a need to evaluate effectiveness of IRB review, no identified published study included an evaluation of IRB effectiveness. Multiple studies evaluating the structure, process, and outcome of IRB review in the United States have documented inconsistencies and inefficiencies. Efforts should be made to address these concerns. Additional research is needed to understand how IRBs accomplish their objectives, what issues they find important, what quality IRB review is, and how effective IRBs are at protecting human research participants.
The IRB process is too important not to undergo periodic evaluation. Evaluations can help an IRB to determine whether it is effectively protecting human subjects, whether it is operating efficiently, and whether it has adequate authority (Office of the Inspector General, 1998a, p. 20) .
Institutional review boards (IRBs), a fixture in the U.S. research firmament (McCarthy, 1996) , review most research involving human participants before it is initiated and at least annually until it is complete. IRBs review research proposals to assure they adhere to federal regulations (Department of Health and Human Services; Federal Drug Administration), include adequate protections of study participants' rights and welfare, and are ethically sound. But, little is known about how well IRBs accomplish these goals.
In recent years, investigators and others have expressed dissatisfaction with the IRB system, criticizing it as dys-functional (Fost & Levine, 2007) , overburdened (Burman et al., 2001 ; Office of the Inspector General, 1998b), and overreaching (Gunsalus et al., 2006) . Clinical investigators complain that the IRB review process is inefficient and delays their research for what seem like minor modifications (Whitney et al., 2008) . Research sponsors object that IRB review is time consuming, leading to delays that can significantly increase the costs of research. The public primarily hears about problems and hence fears that research might be unsafe and existing protections ineffective (Lemonick, Goldstein, & Park, 2002) . The current IRB system has also been described as outdated and inappropriate for the scope and type of research being conducted in the twenty-first century (Maschke, 2008) .
Proposals to reform and improve the IRB system abound, including proposals to centralize, regionalize, or consolidate IRBs, strengthen and demystify federal oversight, infuse more support and resources into the system, augment IRB member training, require credentialing of IRB professionals, mandate independent accreditation, educate the public, and continue to investigate "alternative" models of review (IOM, 2002; NIH, 2006; Steinbrook, 2002) . A common and persistent call for data on IRB quality and a method for monitoring IRB effectiveness is found in various proposals for change.
IRB evaluation has occurred through sporadic auditing or for-cause investigation by research institutions and regulatory agencies such as the U.S. FDA and the DHHS Office of Human Research Protections (OHRP). Events such as the deaths of Jesse Gelsinger at the University of Pennsylvania and a young female employee at Johns Hopkins University, and several high-profile OHRP-initiated suspensions in the last decade, stunned the scientific community, escalated concerns about study oversight, and focused attention on the overburden, inefficiencies, inherent conflicts of interest, inconsistencies, and lack of data about the function and effectiveness of IRBs (Emanuel et al., 2004) .
In 2001, the Association for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP) established a process for accreditation of Human Research Protection Programs described as voluntary, peer driven, and educational. Among other things, AAHRPP determines whether an institution has appropriate arrangements for prospective independent scientific and ethical review and whether the IRB is satisfying federal regulations for review of human subjects research. Accreditation encourages the development of standardized policies and procedures that might lead to improvements in IRB function; however, the focus is primarily on structure and process.
We systematically reviewed available empirical studies evaluating IRBs in order to determine what is known about how well IRBs function and what has been overlooked.
Methods
The goal of this systematic review is to comprehensively describe empirical data on evaluation of IRBs in the United States (Strech, Synofik, & Marckmann, 2008) . A PubMed search was used to identify empirical studies that evaluated IRBs. The final search strategy was limited to English language only and used a combination of Medical Subject Heading (MeSH) terms including ethics committees, research; institutional review boards; and evaluation, program evaluation, outcome assessment, observation, questionnaires, and a few additional subheadings (see Figure 1) . A total of 1,576 English language publications were identified. Personal experiences or anecdotes, literature reviews, and discussions of whether certain types of activity, such as quality improvement, are appropriate for IRB review were excluded. A total of 111 publications reported empirical findings from studies about IRBs or research ethics committees, using either qualitative or quantitative methods. Of these, fifty-nine were excluded because they studied review committees outside of the United States. Forty-three of the remaining fifty-two were included in our analysis. The other studies were analyses of policies or studies of the views of investigators.
Both authors read and categorized each published study into one of the following groups for analysis: (1) studies of IRB structure involving a general description of IRB volume, characteristics of IRB members, or costs associated with IRB review (Table 1) ; (2) process studies examining the extent to which federal regulations are implemented by the IRB (Table 2) ; (3) studies documenting variation in the process or outcome of IRB review in multicenter research (Table 3) ; and (4) outcome studies including those that examine IRB decisions and the results of IRB deliberations (Table 4) . Each table contains information extracted from the published articles about study objectives, methods, results, and conclusions.
Results: What Do We Know About IRBs? Sample Characteristics
Our search identified forty-three empirical studies of various aspects of U.S. IRB structure, process, outcome, or variation in process or outcomes among different IRBs reviewing multicenter studies. A broad array of study methodologies was used, including surveys; analysis of written documents such as IRB minutes, stipulations, and resource utilization data; interviews with IRB members, administrators, or investigators; and site visits. Sample size ranged from analysis of a single IRB (Grodin, Zaharoff, & Kaminow, 1986) to 491 IRBs (Bell, 1998) , and survey responses ranged from ten in one study (McClure et al., 2007) to almost three thousand (2,989) faculty members who serve on IRBs (Campbell et al., 2003) STUDIES OF IRB STRUCTURE-IRB structure studies (n = 16) included evaluation of IRB membership characteristics, IRB costs, the volume of studies reviewed, and the experience of nonaffiliated, nonscientific, and nurse IRB members (see Table 1 ). In several studies, it was reported that IRB members are predominantly white, well-educated, male investigators (Bell, 1998; Campbell et al., 2003; DeVries & Forsberg, 2002; Hayes, Hayes, & Dykstra, 1995) . Financial relationships with industry and financial conflicts of interest were found to be common among medical school faculty members who serve on IRBs as well as among members of academic medical center IRBs (Campbell et al., 2003; Campbell et al., 2006) . Investigators in one study cited lack of necessary administrative support to monitor the volume of ongoing research (DeVries & Forsberg, 2002) . In two studies investigators described a need for role clarification and additional training for the nonscientist and nonaffiliated IRB members (Anderson, 2006; Sengupta & Lo, 2003) . In another study, authors recommended adding more nurse members after comparing the attitudes and perceived influence of physician, nurse, unaffiliated, and other members (Rothstein & Phuong, 2007) . Studies of the costs of IRB operations showed that although IRB costs are highly variable, many IRBs are economically inefficient with large economies of scale favoring high-volume IRBs (Byrne et al., 2006; Sobolski, Flores, & Emanuel, 2007; Wagner et al., 2003; Wagner, Cruz, & Chadwick, 2004) . Importantly, data demonstrated variation in the overall operating and per protocol costs of IRBs of similar size, suggesting that other factors contribute to differences in efficiency. The authors of one study estimated that centralizing review of multisite protocols could result in a 10-35% cost savings (Sobolski et al., 2007) , although it was noted that few IRBs track whether the studies they review are multisite.
The need for standards for measuring IRB quality and efficiency was recognized early in the evolution of IRBs, but never realized. For example, in the 1970s the U.S. National Commission recruited Bradford Gray and colleagues to evaluate IRBs and assess their effectiveness. After an intensive review of a single IRB (Gray, 1975) and later a larger survey of IRB members and investigators from 421 institutions (Cooke, Tannenbaum, & Gray, 1977) , they concluded that lack of performance evaluation with objective measures hindered assessment of IRB impact and that serious efforts to understand and improve IRB performance were needed.
Concern in the 1990s about the federal oversight process and its effectiveness in protecting human subjects from harm led to two federal reviews, one by the U.S. Government Accounting Office (GAO, 1996) and another by the Inspector General's (IG) Office of the Department of Health and Human Services (Office of the Inspector General, 1998a General, , 1998b General, , 1998c . Both warned that IRBs are under pressure because of increasing workload without adequate support or resources. The GAO concluded that current oversight mechanisms were preventing major abuses, but that measures of IRB performance were lacking. The IG, in contrast, concluded that IRBs' ability to safeguard the rights and welfare of human research subjects was seriously strained because of the high volume of studies and pervasive conflicts of interest.
In sum, the studies in this section recommended increasing the diversity of IRB membership and enhancing their training, managing IRB member conflicts of interest, decreasing IRB costs by consolidating and centralizing IRB review, and developing performance measures for IRBs.
STUDIES OF IRB PROCESS-Five
studies evaluated a particular aspect of the IRB review process (see Table 2 ). In one qualitative study, IRB members were interviewed about the process of reviewing emergency research with a consent exemption. The authors concluded that although IRB members found the community consultation requirement vague and difficult to implement, current regulations, if properly adhered to, would adequately protect subjects (McClure et al., 2007) . In a survey about pediatric assent requirements, half of 188 IRB chairs said they used a standard age at which they required assent, while the other half relied on investigators' judgment (Whittle et al., 2004 ). An analysis of FDA warning letters to hospital, university, and commercial IRBs included citations for process failures, such as failure to have or follow adequate written procedures for research review; to prepare and maintain adequate documentation; and to conduct adequate continuing review (Bramstedt & Kassimatis, 2004) . A review of OHRP compliance oversight determination letters found that citations of non-compliance were primarily for deficiencies in following the regulations for initial IRB review and deficiencies in consent documents (Weil et al., 2010) . A study commissioned by the President's Commission (President's Commission, 1983) concluded that IRB processes could feasibly be evaluated through peer site visits. The studies in this group recommended clearer guidance and training for IRB members, more consistent application of federal regulations, and methods for evaluation of IRB performance.
STUDIES OF MULTICENTER VARIATION IN PROCESS AND OUTCOME-A
subset of published empirical studies of IRBs (n = 16) evaluated variation in the processes and/or outcomes of review by different IRBs for multicenter studies (see Table 3 ). In each of these studies, the same research proposal was submitted to IRBs at multiple sites, and data were collected that demonstrate considerable variation among them in the type of review required (Dziak et al., 2005; Larson et al., 2004; McWilliams et al., 2003) ; the time it took to review the proposed research (Clark et al., 2006; Dziak et al., 2005; Green, Lowery, & Wyszewianski, 2006; Greene, Geiger, & Harris, 2006; Helfand et al., 2009; Hirshon et al., 2002; Larson et al., 2004; Mansbach et al., 2007; Stair et al., 2001 ); the designation of risk level (Mansbach et al., 2007; McWilliams et al., 2003) ; acceptable methods for recruitment of subjects (Clark et al., 2006; Silverman, Hull, & Sugarman, 2001) ; the number and type of IRB concerns expressed or changes required (Clark et al., 2006; Green et al., 2006; S. Greene et al., 2006; Helfand et al., 2009; Stair et al., 2001; Stark, Tyson, & Hibberd, 2009; Sherwood et al., 2006) ; and the IRB determination (Stair et al., 2001; Stark et al., 2009) . Variation in informed consent practices and inadequacies in regulatory completeness of the consent forms were documented in one study (Silverman et al., 2001) , and variation in cost in another (Vick et al., 2005) . Further, study investigators argued that inconsistencies can have negative consequences for investigators, for research participants, and for the integrity of the science. All studies in this section recommended the development of a process for multicenter review to increase efficiency and reduce variation.
STUDIES OF IRB OUTCOME-Particular outcomes beyond multicenter variation in review practices and outcomes were evaluated in six studies, and again considerable variation among IRBs was shown (see Table 4 ). In one study, wide differences were noted in IRB decisions about compensation and assent in pediatric research (Kimberly et al., 2006) . In another study in which IRB chairs rated the risk level of certain pediatric research procedures, only a single blood draw was rated as minimal risk by the majority (Shah et al., 2004) . Burman and colleagues found that for a centrally approved TB protocol, most IRBs made no changes in the protocol, but requested consent form changes that made the forms longer and more complex (Burman et al., 2003) . Another study documented variation from existing guideline recommendations in consent forms for research with stored samples (White & Gamm, 2002) . A survey of multiple IRBs showed the most common reason for rejection of studies was problems with informed consent (Jones et al., 1996) . A final study in this group showed that the majority of proposals reviewed by one IRB over twelve years were approved with stipulations; no proposals were rejected (Grodin et al., 1986) . The studies in this section showed that IRBs have different views about the level of risk of common procedures, that IRB-requested changes make consent forms longer and more complex, and that although no studies were rejected in a study of one IRB, in another study of multiple IRBs the majority of rejections were related to the consent document.
Discussion
This systematic review of empirical studies of IRBs provides valuable information about what we know about IRBs and points to critical gaps in our knowledge. Considerable effort has been expended over several decades to evaluate and document practices, inconsistencies, and variation in the structures, processes, and outcomes of IRB review. These data from forty-three published studies show that U.S. IRBs differ in their application of the same set of regulations and are somewhat inconsistent in their judgments.
Data presented in this review provide support to commentators who have complained about inconsistencies, delays, inefficiencies, "redundant reviews in multi-site trials, and needless tinkering with consent forms" (NIH, 2006) for many kinds of studies reviewed by U.S. IRBs. Overwhelmingly, these data show that IRB practices and decisions, including determinations of which studies require full or expedited review, whether the level of risk was minimal or greater than minimal, and practices related to recruitment, vary from IRB to IRB, often without a clear justification for the variation.
Of note, investigators of several of these studies suggest that changes required by individual IRBs can sometimes jeopardize the scientific integrity of multicenter studies and national studies. Data also suggest that difficulty and delays with the local IRB approval process sometimes result in sites or investigators choosing not to participate in research (Mansbach et al., 2007) . The extent to which IRB review inhibits important and ethically appropriate research is not known, but potentially troublesome.
Although some data suggest that IRBs focus on consent documents, little is documented about other issues that IRBs consider important to their decisions or about the substance of IRB deliberations. Although investigators of reviewed studies and other commentators have repeatedly called for measures of IRB quality and effectiveness, we could not identify one study that evaluated the effect that IRB review has on the protection of human subjects.
Investigators of reviewed studies document substantial inefficiencies in existing structures for IRB review, and many argue that centralizing review for multicenter studies would not only be more efficient, but better for the integrity of the science without jeopardizing protection of human subjects. The National Cancer Institute, the Veterans' Administration, and others have important central IRB review initiatives for multisite studies, and such initiatives are likely to expand (NCI Central IRB Initiative; VA Central Institutional Review Board). However, some are reluctant to use central review principally because of belief in the value of local input and concerns about local institutional liability (Loh & Meyer, 2004) . Possible positive aspects of local review might include knowledge of the local participant populations and the local investigators, and opportunities for mentoring junior investigators and research staff (NIH, 2006) . Research documenting the advantages of local review over central review in protecting research participants would be useful to informing decisions about review. Commentators have proposed centralizing or regionalizing review for all studies-not just multicenter-with the goal of increasing review efficiency and quality (Wood, Grady, & Emanuel, 2004) . Data on how well each model protects participants, as well as how they differ with regard to efficiency, the major issues identified, and costs, would be valuable in considering these options.
Investigators of the studies reviewed here and numerous commentators yearn for more efficiency and less variation in IRB review (Byrne et al., 2006; Emanuel et al., 2004; Fost & Levine, 2007; Goldman & Katz, 1982; Helfand et al., 2009; Hirshon et al., 2002; Kimberly et al., 2006; Larson et al., 2004; NIH, 2006; OIG, 1998b; Silverman et al., 2001; Vick et al., 2005; Wagner et al., 2004; Whittle et al., 2004; Wood et al., 2004) . There is no apparent reason that IRB review of the same protocol at one institution can be completed in a week, while at another institution it takes thirty or more weeks. Efficiency-achieving a desired outcome with a minimum expenditure of time, effort, and resources-is an important value, as is a responsive process that does not needlessly delay research. Efficiency, however, requires clarity about the desired outcome or result. Simply measuring and shortening the time from IRB submission to approval (although likely to be appreciated for many reasons) may be insufficient for improving efficiency. Measures of IRB quality or metrics to show whether or not an IRB achieves the desired results in an efficient manner are also necessary. As noted in the summary of an NIH workshop on Alternative Methods of Review, "Issues to resolve include a clear understanding of what `quality' really means in a review and how it can be measured" (NIH, 2006) . Furthermore, variation, in and of itself, can be legitimate and not necessarily problematic (Edwards, Ashcroft, & Kirchin, 2004) . Unjustified variation, however, can be problematic, and as noted, variation in assessment of risk or application of certain regulations can jeopardize the science or contribute to decreased research productivity and increased expense without enhancing protections. Variation in IRB process and outcomes was repeatedly demonstrated in studies reviewed here. Early studies (Goldman & Katz, 1982; Gray, 1975) conducted with the explicit expectation that IRBs would apply similar criteria and reach similar conclusions about a protocol instead found substantial inconsistencies. Although flaws have been noted in their study (Levine, 1984) , in 1982, Goldman and Katz said, "These findings [of inconsistency] cast doubt on the adequacy of IRB decision-making and the effectiveness of regulations" (Goldman & Katz, 1982) . Multiple studies over the ensuing decades have repeated this finding and expressed similar concerns. Some level of dissimilarity in interpretation of the regulations might be expected in a system of local review. What has not been addressed, however, is the justification for variation and how variation contributes to protection of human subjects. Importantly, some variation-for example, where one or more IRBs determine that a particular study is too risky to approve and others expedite the same study as minimal risk-seems irrational and could feasibly impact both safety and scientific rigor (Goldman & Katz, 1982; Mansbach et al., 2007; McWilliams et al., 2003; Rogers et al., 1999; Stark et al., 2009) . Since the goal of the IRB is to safeguard the rights and welfare of human subjects in research, it is critical to determine the extent to which differences in review processes or outcomes thwart or uphold this objective.
Alternative models to the single institutional IRB should continue to be utilized and evaluated (Maschke, 2008; NIH, 2006) . In addition to concern about wide differences in outcome and the time and resources expended to review and revise a single proposal numerous times for multisite studies, evidence is needed regarding what protections multiple IRB reviews add. Studies are also needed to evaluate how well centralized review achieves quality and efficient review of research. Well-defined metrics will be crucial to making these determinations.
Much can be learned from available data on IRBs in the United States, including that (1) IRB members need and want more guidance or training; (2) IRB membership could be more diverse; (3) the volume of IRB workload varies by institution, and the costs per review are generally lower in programs that review a higher volume of studies; (4) interpretation of federal regulations varies among IRBs, and additional guidance or clarification about how to apply the regulations would be seen as helpful; (5) the review of multisite studies of various kinds by multiple IRBs is inefficient, perceived as burdensome, and results in changes to research proposals that could affect the quality of the science; (6) IRB decisions differ about compensation, risk level, recruitment methodologies, and other important aspects of research without explanation for the differences; and (7) IRBs frequently recommend changes to consent documents, but changes do not always ensure compliance with existing recommendations. In addition to addressing these documented problems and inconsistencies, proposals continue to call for assessment of the impact of IRB review on protection of human subjects (Taylor, 2007; Candilis, Lidz, & Arnold, 2006; Coleman & Bouesseau, 2008) . The impact of IRB review on the protection of subjects has proven difficult to measure, yet efforts are needed to identify and test appropriate, well-defined, acceptable, and useful metrics to determine how well IRBs accomplish their objectives, and how they can do so in an efficient and reasonable manner.
Best Practices
IRBs or others that have developed mechanisms or best practices for enhancing efficiency, for documenting the rationale for their decisions, for justifying variation, for reducing costs, or for measuring IRB quality should share these with other IRBs and interested parties.
Research Agenda
As described above, considerable additional research would be valuable in informing the future structure and organization, processes, and outcomes of IRBs in the U.S. An important overarching question is, What do we expect from IRBs? Clarifying expectations is important to being able to measure effectiveness. For example, should we expect IRBs to be more consistent at determining the risk of certain procedures or the risk level of a study? In protecting subjects from risk, could we examine how IRBs minimize risk? Or how changes in study proposals required by the IRB protect participants from risk? Centralized data on the risks that research participants experience would also be helpful in this regard. We might determine, perhaps through interviewing a subset of investigators in different areas, how often studies are not done (and what kind of studies) or how often investigators or sites chose not to be involved in a study because IRB review is a deterrent. It would be helpful to investigate how often IRBs disapprove studies and on what basis; or similarly, how often IRBs approve studies without any stipulations. Ethnographic studies of IRB meetings or studies of IRB minutes could help to identify the primary issues that IRBs consider in their review of research proposals and where there are gaps. Importantly, efforts should be made to identify and test metrics for measuring the quality of IRB review and the effect of IRB review on protection of human subjects. It may be necessary to first develop a consensus view on how IRB quality should be understood. Studies could then investigate how quality differs by IRBs, what accounts for the differences, and how to identify best practices. Studies might compare local review and central review with respect to the quality of IRB discussions, attention to important issues, outcome determinations, costs, efficiency, and other factors. Work should be done to identify areas of variation that might be acceptable or even justifiable between IRBs reviewing the same study. Studies should also be done to investigate what changes are stipulated by IRBs in consent forms, and what impact these changes have on the research participants' understanding. Evaluation of different strategies used at IRB meetings-e.g., the use of primary and secondary reviewers, checklists, or a standard set of specific questions-would be useful. Additional helpful studies could evaluate the effect on investigator satisfaction, IRB efficiency, and the focus of the pre-IRB review by an IRB coordinator or administrator to make sure that the written submission is complete and addresses regulatory issues.
Educational Implications
Data show that IRB members would benefit from, and express a desire for, additional training regarding protection of human subjects. Existing educational programs about the federal regulations and interpretive guidance should be available to all IRB members, and updated periodically. In addition, education about the function and merits of IRB review continues to be valuable for the important stakeholders, including investigators, institutional officials, and research participants. IRB has an impact on research performance, but lack of monitoring and feedback from subjects limits the impact on the actual conduct of the study. (1) These studies require lengthy review.
(2) Community consultation and notification is vague and difficult to implement.
(3)
Current regulations protect human subjects.
(4)
Legal counsel is important. Mean time to complete approval was 2.9 +/−1.5 months. Estimated $53,000 spent on staff salary dedicated to IRB process (24% of first-year study budget).
The IRB process for multisite study is expensive in both time and money. National VA IRB is recommended. Highly variable review process among the IRBs. Evaluation of the risk of the same study ranged from minimal to high -7 expedited, 24 full board reviews. IRBs required between 1 and 4 consents for this study.
Multisite studies are important to advances in human genome and genetic studies affecting the public health. Recommend centralized review to reduce variability in human subjects protection and promote efficiency. Hirshon et al. 2002 (49) Examine IRB variability in response to a minimal-risk survey of emergency room providers and people in the ER waiting area
Research survey submitted to IRBs at 3 different institutions
One institution reviewed the study in 12 business days and waived informed consent, a second took 15 days in expedited review, the third took 77 days and required 3 revisions, including study methodology, sample size, and recruitment strategies.
Review inconsistencies raise questions about the validity and efficiency of the IRB process. There is a need for standardization of the minimal risk review process to decrease variability and therefore improve the validity of the process. Stair et al. 2001 (45) Examine IRB variation in responses to a phase 4 multicenter, randomized, doubleblind, placebocontrolled trial of Survey of investigators participating in a single, standard multisite protocol at 44 sites Median time from protocol delivery to approval was 102 days (8-142); an average of 3.5 changes were requested; 91% of them consent changes; 82% of protocols were returned from 1 to 4 times for The use of a national IRB could focus on the scientific aspects of the study, leaving the properly local consent issues to local IRBs. Standardized submittal forms
